chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 14.0
Sex: F
Vaccine: COVID19-2
Symptoms: Expired product administered
Clinical narrative: Patient received COVID shot after beyond use date.
Age: 18.0
Sex: M
Vaccine: COVID19-2
Symptoms: Expired product administered
Clinical narrative: COVID VACCINE ADMINISTERED PAST BEYOND USE DATE OF 12/17/2022.
Age: 82.0
Sex: F
Vaccine: FLUA4, RSV
Symptoms: Abdominal pain upper, Arthralgia, Back pain, Pain in extremity
Clinical narrative: Patient went to bed at night on 8/18/23.  She felt pain in her stomach lik glass cutting her stomach. It stopped 8/19/23 in AM.  Then in AM of 8/19/23 she felt arthritic pain in legs, thighs + back Went away by 8/21/23
Age: 12.0
Sex: M
Vaccine: COVID19-2
Symptoms: Expired product administered
Clinical narrative: Patient received COVID shot after beyond use date of 12/17/2022.
Age: 12.0
Sex: M
Vaccine: COVID19-2
Symptoms: Expired product administered
Clinical narrative: PATIENT WAS GIVEN COVID VACCINE AFTER BEYOND USE DATE OF 12/17/2022
Age: 71.0
Sex: F
Vaccine: FLU4
Symptoms: Diarrhoea, Injection site bruising, Lethargy, Nausea, Pain in extremity
Clinical narrative: NAUSEA, DIARRHEA, EXTREME PAIN IN LEFT ARM, SEVERE BRUISING AROUND INJECTION SITE; LETHARGIC FOR ABOUT 2 DAYS
Sex: M
Vaccine: UNK, UNK
Symptoms: Pain, Product administered at inappropriate site
Clinical narrative: Patient states vaccines were painful. Upon visible inspection vaccines were given high on both shoulders
Age: 34.0
Sex: F
Vaccine: HPV9
Symptoms: Exposure during pregnancy, No adverse event
Clinical narrative: No additional AE; Patient that did not disclose pregnancy prior to receiving GARDASIL 9.; This spontaneous report was received from a nurse and refers to a 34-year-old pregnant female. The patient's medical history included blood thyroid stimulating hormone decreased, alpha-thalassemia silent carrier, pyelectasis of fetus, and vitamin D deficiency. Her drug reactions/allergies, concurrent conditions, and concomitant therapies were not reported. The patient was in the 25h pregnancy week. The patient's last menstrual period was estimated to be on as 02-FEB-2023, date of conception was estimated to be on 16-FEB-2023 and the due date on 09-NOV-2023.  On an unspecified date, the patient was vaccinated with human papillomavirus (HPV) rl1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast) (GARDASIL 9) injection, 0.5 milliliter, administered intramuscularly as human papilloma virus (HPV) vaccination (strength, frequency, lot #, expiry date, and anatomical location were not provided).  It was reported that the patient did not disclose pregnancy prior to receiving human papillomavirus (HPV) rl1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast) (GARDASIL 9) (exposure during pregnancy) (onset date reported as 21-JUL-2023). No symptoms or additional adverse events were reported (no adverse event). On 24-JUL-2023, the patient recovered from the event and no treatment was given. At the time of reporting, pregnancy outcome was pending and fetal outcome was unknown.
Sex: U
Vaccine: MMR
Symptoms: Product storage error
Clinical narrative: No other AE and no PQC; HCP calling to report an administration of MMR II following a not supported temperature excursion.  HCP confirms no symptoms have been reported and no further details provided.  No other AE and no PQC; This spontaneous report has been received from a physician, referring to a patient of unknown age and gender. The patient's medical history, concurrent conditions and concomitant medications were not reported.  On 31-JUL-2023, the patient received measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) injection, lot #W022944, expiration date was not reported but it was stablished upon internal validation as 06-APR-2024, administered for prophylaxis (strength, and route of administration were not provided). The vaccine was administered following a not supported temperature excursion. The physician confirmed that no symptoms were reported.
Sex: U
Vaccine: MMRV
Symptoms: No adverse event, Product storage error
Clinical narrative: No additional AEs or PQC reported; Caller reported vaccine administered after temperature excursions; This spontaneous report was received from a registered nurse and refers to a patient of unknown age and gender. Information regarding the patient's concomitant therapies, concurrent conditions, medical history and historical drugs was not provided.  On 29-JUL-2023, the patient started therapy with measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) injection, 0.5 milliliter, lot #W038809 rHA , expiration date: 04-JUN-2024, administered intramuscularly for prophylaxis (strength was not provided).  The improperly stored dose of the suspect vaccine experienced a temperature excursion of 18.3 degree fahrenheit for 1 hour and 5 minutes; no previous temperature excursions were reported.  No adverse symptoms were reported.
Sex: U
Vaccine: MMRV
Symptoms: No adverse event, Product storage error
Clinical narrative: No additional AEs or PQC reported; Caller reported vaccine administered after temperature excursions; This spontaneous report was received from a registered nurse and refers to a patient of unknown age and gender. Information regarding the patient's concomitant therapies, concurrent conditions, medical history and historical drugs was not provided.  On 29-JUL-2023, the patient was vaccinated with measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) injection, 0.5 milliliter, lot #W038809 rHA , expiration date: 04-JUN-2024, administered intramuscularly for prophylaxis (strength was not provided).  The improperly stored dose of the suspect vaccine experienced a temperature excursion of 18.3 degree fahrenheit for 1 hour and 5 minutes; no previous temperature excursions were reported.  No adverse symptoms were reported.
Sex: U
Vaccine: VARCEL
Symptoms: No adverse event, Product storage error
Clinical narrative: No additional AEs or PQC reported; Caller reported vaccine administered after temperature excursions; This spontaneous report was received from a registered nurse and refers to a patient of unknown age and gender. Information regarding the patient's concomitant therapies, concurrent conditions, medical history and historical drugs was not provided.  On 29-JUL-2023, the patient was vaccinated with varicella virus vaccine live (oka/merck) (VARIVAX) injection, 0.5 milligram, lot #X006983, expiration date: 07-MAR-2025, administered intramuscularly for prophylaxis (strength was not provided).  The improperly stored dose of the suspect vaccine experienced a temperature excursion of 18.3 degree fahrenheit for 1 hour and 5 minutes; no previous temperature excursions were reported.  No adverse symptoms were reported.
Sex: U
Vaccine: VARCEL
Symptoms: No adverse event, Product storage error
Clinical narrative: No additional AE; patient receiving VARIVAX after it was improperly stored; This spontaneous report was received from a pharmacist and refers to a patient of unknown age and gender. Information regarding the patient's concurrent conditions, medical history, historical drugs and concomitant therapies was not provided.  On 11-JUL-2023, the patient received 1 dose of an improperly stored varicella virus vaccine live (oka/merck) (VARIVAX) subcutaneous injection, lot #X001000, expiration date: 09-JAN-2025, administered for prophylaxis (strength, and route of administration were not provided) (product storage error). No additional adverse events reported.
Sex: U
Vaccine: MMRV
Symptoms: Expired product administered, No adverse event
Clinical narrative: No additional AE reported; HCP called to report they inadvertently administered expired PROQUAD vaccine to a patient on 8/14/2023; This spontaneous report was received from a medical assistant and refers to a patient of unknown age and gender. Information regarding the patient's concomitant therapies, concurrent conditions, medical history and historical drugs was not provided.  On 14-AUG-2023, the patient was vaccinated with measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) injection, 1 dosage form, lot #W004694 rHA, expiration date: 08-AUG-2023 (Expired product administered), administered for prophylaxis (strength, and route of administration were not provided).  No adverse symptoms were reported.
Age: 8.0
Sex: M
Vaccine: HPV9
Symptoms: Product administered to patient of inappropriate age
Clinical narrative: Child received his first GARDASIL 9 dose at the age of 8 years and 8 months; No symptoms reported; This spontaneous report was received from a nurse, referring to an 8-year-old male patient. The patient's medical history, concurrent conditions, and concomitant therapies were not reported.  On an unknown date, the patient was vaccinated at the age of 8 years and 8 months with the first dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) injection, administered for prophylaxis (strength, dose, lot #, expiry date, and route of administration were not provided) (product administered to patient of inappropriate age). No symptoms were reported.
Age: 17.0
Sex: M
Vaccine: HEP
Symptoms: Incorrect dose administered, No adverse event
Clinical narrative: No additional AE; the HCP administered a 1 ml adult dose of the hepatitis B vaccine to her son instead of the pediatric formulation of the 0.5ml dose; This spontaneous report was received from a consumer and refers to her son, a currently 36 years old male patient. Information regarding the patient's concurrent conditions, medical history, historical drugs and concomitant therapies was not provided.  The reporter informed that her son received an adult formulation dose of possibly hepatitis b vaccine (recombinant) (RECOMBIVAX HB) intramuscular injection, administered for prophylaxis (strength, lot #, expiry date, and route of administration were not provided) at the age of 17 years old back in May 2005. Caller is unsure of the name of the hepatitis B vaccine that he received but stated that it could possibly have been hepatitis b vaccine (recombinant) (RECOMBIVAX HB). The reporter stated that the healthcare professional (HCP) administered a 1 ml adult dose of the vaccine to her son instead of the pediatric formulation of the 0.5ml dose because the HCP stated that "his weight is heavy enough for the adult dose" (Incorrect dose administered). No additional adverse events reported.
Sex: U
Vaccine: MMR, VARCEL
Symptoms: Antibody test abnormal
Clinical narrative: titers for measles and varicella that were "too low."; This spontaneous report was received from a nurse and refers to a currently 23 years old patient. Information regarding the patient's concurrent conditions and medical history was not provided.   The reporter informed that the patient received 2 doses of measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) and varicella virus vaccine live (oka/merck) (VARIVAX) on an unknown date in the past and afterwards showed titers for measles and varicella that were "too low" (antibody test abnormal). The patient then received a dose of measles (+) mumps (+) rubella and varicella (oka-merck) virus vaccine live (PROQUAD) for a "booster dose" in May 2023. No additional adverse events reported.  The causal relationship between he event and suspect therapies was unknown.
Age: 61.0
Sex: F
Vaccine: HEP, VARZOS
Symptoms: Dizziness, Hyperventilation, Hypoaesthesia, Loss of consciousness, Musculoskeletal stiffness
Clinical narrative: after administering both shots, the patient started complaining of dizziness. A few seconds after she seized for  less then 10  seconds and then passed out for about 10 seconds.  When she came through, she began to complain of her inability to feel her hands and legs. I noticed that her fingers became a little stiff. She was also hyperventilating all through the process.  Her vitals remained steady through the whole ordeal.  She began to feel a little better when the EMTs came in.  She was fully aware and able to communicate her feelings after the seizure and fainting and seemed to be recovering
Age: 61.0
Sex: F
Vaccine: HEP, VARZOS
Symptoms: Seizure
Clinical narrative: after administering both shots, the patient started complaining of dizziness. A few seconds after she seized for  less then 10  seconds and then passed out for about 10 seconds.  When she came through, she began to complain of her inability to feel her hands and legs. I noticed that her fingers became a little stiff. She was also hyperventilating all through the process.  Her vitals remained steady through the whole ordeal.  She began to feel a little better when the EMTs came in.  She was fully aware and able to communicate her feelings after the seizure and fainting and seemed to be recovering
Age: 15.0
Sex: F
Vaccine: HPV9, IPV, MNQ
Symptoms: Blood glucose, Syncope
Clinical narrative: Around 4:20PM -  had 3 series of vaccines last given was HPV  patient at the time was sitting , after vaccines was administer 2 minutes later patient fainted , collapse on the floor. MA helped mom moved pt away from any danger. called for helped Provide on Duty and PCP assisted .  BP . Hr and glucose was taken . Once patient regain consciousness, drank some water and snacks after approximate 40mins  . pt was stable , both parents took patient to the nearest ED
Age: 11.0
Sex: M
Vaccine: MNQ
Symptoms: Incorrect dose administered, Product preparation error
Clinical narrative: improper dose of Menveo on 08/09/2023 reconstituted with sterile diluent.; improper dose of Menveo on 08/09/2023 reconstituted with sterile diluent.; This non-serious case was reported by a other health professional via call center representative and described the occurrence of wrong solution used in drug reconstitution in a 11-year-old male patient who received Men ACWY-CRM NVS (Menveo) (batch number AMVA769A, expiry date 31-JAN-2024) for prophylaxis.   On 09-AUG-2023, the patient received Menveo. On 09-AUG-2023, an unknown time after receiving Menveo, the patient experienced wrong solution used in drug reconstitution (Verbatim: improper dose of Menveo on 08/09/2023 reconstituted with sterile diluent.) and inappropriate dose of vaccine administered (Verbatim: improper dose of Menveo on 08/09/2023 reconstituted with sterile diluent.). The outcome of the wrong solution used in drug reconstitution and inappropriate dose of vaccine administered were unknown.   Additional Information: GSK receipt date 16 August 2023: The medical assistant reporting having administered an improper dose of Menveo on 9 August 2023 reconstituted with sterile diluent. The reporter consented to follow up.  The Vaccine Administration Facility was the same as primary reporter. The patient administered an improper dose of Menveo reconstituted with sterile diluent, which led to wrong solution used in drug reconstitution and inappropriate dose of vaccine administered.
Age: 50.0
Sex: F
Vaccine: COVID19-2
Symptoms: Expired product administered, No adverse event
Clinical narrative: No adverse event; Administered a Moderna booster that expired on June12,2023; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Administered a Moderna booster that expired on June12,2023) and NO ADVERSE EVENT (No adverse event) in a 6-decade-old female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 045H22A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 04-Aug-2023, the patient received fourth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 04-Aug-2023,  after starting mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)), the patient experienced EXPIRED PRODUCT ADMINISTERED (Administered a Moderna booster that expired on June12,2023). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Administered a Moderna booster that expired on June12,2023) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (Administered a Moderna booster that expired on June12,2023).    This case was created for female patient of the 2 patients involved.  Patients age was reported as 50s. Concomitant medication was not provided. Treatment information was not reported.   This case was linked to US-MODERNATX, INC.-MOD-2023-736628 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-736628:Male patient case
Age: 26.0
Sex: F
Vaccine: COVID19
Symptoms: Cough, Heavy menstrual bleeding, Parosmia, Taste disorder
Clinical narrative: chronic cough; smell and taste have been altered /losses; smell and taste have been altered /losses; heavier menstrual cycle; This spontaneous case was reported by a consumer and describes the occurrence of COUGH (chronic cough), PAROSMIA (smell and taste have been altered /losses), TASTE DISORDER (smell and taste have been altered /losses) and HEAVY MENSTRUAL BLEEDING (heavier menstrual cycle) in a 26-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 037B21A) for COVID-19 prophylaxis.     The patient's past medical history included COVID-19 in December 2021. Concomitant products included ZINC and VITAMIN B COMPLEX (VITAMIN B CO) for an unknown indication.    On 09-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular use) .5 milliliter. On an unknown date, the patient experienced COUGH (chronic cough), PAROSMIA (smell and taste have been altered /losses), TASTE DISORDER (smell and taste have been altered /losses) and HEAVY MENSTRUAL BLEEDING (heavier menstrual cycle). At the time of the report, COUGH (chronic cough) had not resolved and PAROSMIA (smell and taste have been altered /losses), TASTE DISORDER (smell and taste have been altered /losses) and HEAVY MENSTRUAL BLEEDING (heavier menstrual cycle) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular use) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular use), the reporter did not provide any causality assessments.   It was unknown if the patient experienced any additional symptoms/events. The patient had no medical history, concomitant disease or risk factor. It was unknown if there were additional lab data/results available.
Sex: U
Vaccine: VARZOS
Symptoms: Incomplete course of vaccination
Clinical narrative: first dose of Shingrix but not the second within the recommended time; This non-serious case was reported by a other health professional via sales rep and described the occurrence of incomplete course of vaccination in a patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (1st dose received on an unknown date).   On an unknown date, the patient did not receive the 2nd dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced incomplete course of vaccination (Verbatim: first dose of Shingrix but not the second within the recommended time). The outcome of the incomplete course of vaccination was unknown.   Additional Information: GSK receipt date: 15-AUG-2023 and 16-AUG-2023 The reporter enquired that, what should a patient that took the first dose of Shingrix but not the second within the recommended time frame? MI did not speak with the Health Care Provider, so please follow up with the Sales Representative for more information.  Till the time of reporting, the patient did not receive 2nd dose of Shingrix, which led to incomplete course of vaccination.
Sex: F
Vaccine: VARZOS
Symptoms: Inappropriate schedule of product administration, Incomplete course of vaccination
Clinical narrative: Inappropriate Schedule of Vaccine; This non-serious case was reported by a consumer via call center representative and described the occurrence of incomplete course of vaccination in a 68-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (received 1st dose in 2019, in an unknown arm, Intramuscularly).   On an unknown date, the patient did not receive the 2nd dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced incomplete course of vaccination (Verbatim: Inappropriate Schedule of Vaccine). The outcome of the incomplete course of vaccination was unknown.   Additional Information: GSK receipt date: 16 August 2023: The patient reported that she received her first Shingrix vaccine sometime in 2019, in an unknown arm. She now finds out from the pharmacy that there was supposed to be a second Shingrix vaccine in 2 to 6 months from the first to complete the series.  The reporter did not consent to follow-up. Till the time of reporting the patient did not received 2nd dose of Shingrix which led to incomplete course of vaccination.; Sender's Comments:  US-GSK-US2023111557:Same reporter, different patient
Sex: M
Vaccine: VARZOS
Symptoms: Incomplete course of vaccination
Clinical narrative: first dose of Shingrix in December of 2021 and has not received a second dose yet; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of incomplete course of vaccination in a 65-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (received 1st dose in December 2021).   On an unknown date, the patient did not received the 2nd dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced incomplete course of vaccination (Verbatim: first dose of Shingrix in December of 2021 and has not received a second dose yet). The outcome of the incomplete course of vaccination was unknown.   Additional Information: GSK receipt date 17 August 2023: The pharmacist reported a patient received their first dose of Shingrix in December of 2021 and had not received a second dose yet.  The reporter consented to follow up.  The Vaccine Administration Facility was the same as Primary Reporter. Till the time of reporting the patient did not received 2nd dose of Shingrix which led to incomplete course of vaccination.
Sex: F
Vaccine: VARZOS, VARZOS
Symptoms: Herpes zoster, Incomplete course of vaccination
Clinical narrative: she developed shingles; never got the 2nd dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of shingles in a 70-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix and the 2nd dose of Shingrix. On an unknown date, 6 weeks after receiving Shingrix and not applicable after receiving Shingrix, the patient experienced shingles (Verbatim: she developed shingles) and incomplete course of vaccination (Verbatim: never got the 2nd dose). The outcome of the shingles and incomplete course of vaccination were unknown.   It was unknown if the reporter considered the shingles to be related to Shingrix.     It was unknown if the company considered the shingles to be related to Shingrix.   Additional Information: GSK receipt date: 17-AUG-2023 The pharmacist reported that patient received 1st dose of Shingrix in the beginning 2020 but never got the 2nd dose. 6 weeks back she developed shingles but not active? Till the time of reporting, the patient did not receive 2nd dose of Shingrix, which led to incomplete course of vaccination. This case was found as duplicate of case US2023112146. All the information from the case US2023112146 was merged into this case. The case US2023112146 was deleted and this case stand as case of record for this patient. The reporter consented to follow up.
Age: 87.0
Sex: M
Vaccine: COVID19
Symptoms: Abdominal pain, COVID-19 pneumonia, Chest pain, Diarrhoea, Dyspnoea
Clinical narrative: Chief Complaint:SOB.  diarrhea, abd pain, and CP.  Pneumonia due to COVID-19 virus   Hypoxia developed during ER stay   -start dexamethasone   -oxygen support
Age: 87.0
Sex: M
Vaccine: COVID19
Symptoms: Hypoxia
Clinical narrative: Chief Complaint:SOB.  diarrhea, abd pain, and CP.  Pneumonia due to COVID-19 virus   Hypoxia developed during ER stay   -start dexamethasone   -oxygen support
Age: 65.0
Sex: M
Vaccine: COVID19
Symptoms: Breath sounds abnormal, COVID-19, COVID-19 pneumonia, Chest X-ray abnormal, Cough
Clinical narrative: pt presents with Covid-19 Patient states covid positive with vaccination. Tested positive on 25th, states o2 was low at home. O2 is good here.  Positive for cough.  Decreased breath sounds present. low O2 sat reading. Ambulatory O2 sat of 88% and placed on 2L nasal cannula. CXR shows Covid-19 PNA.  Initiated on steroids-Decadron, azithromycin and O2 supplementation to maintain sats in 90s
Age: 65.0
Sex: M
Vaccine: COVID19
Symptoms: Oxygen saturation decreased, SARS-CoV-2 test positive
Clinical narrative: pt presents with Covid-19 Patient states covid positive with vaccination. Tested positive on 25th, states o2 was low at home. O2 is good here.  Positive for cough.  Decreased breath sounds present. low O2 sat reading. Ambulatory O2 sat of 88% and placed on 2L nasal cannula. CXR shows Covid-19 PNA.  Initiated on steroids-Decadron, azithromycin and O2 supplementation to maintain sats in 90s
Age: 90.0
Sex: F
Vaccine: COVID19
Symptoms: Acute kidney injury, Anaemia, COVID-19, Dyspnoea, Laboratory test abnormal
Clinical narrative: swelling in legs, SOB, loss of 20 lbs; seen in ER received 1 L of fluids. labs showed AKI and anemia.referred for inpt for further management.  DX with COVID 19 w/out hypoxia.
Age: 90.0
Sex: F
Vaccine: COVID19
Symptoms: Peripheral swelling, Weight decreased
Clinical narrative: swelling in legs, SOB, loss of 20 lbs; seen in ER received 1 L of fluids. labs showed AKI and anemia.referred for inpt for further management.  DX with COVID 19 w/out hypoxia.
Age: 64.0
Sex: M
Vaccine: COVID19
Symptoms: Acute respiratory failure, COVID-19, Cough, Dizziness, Exposure to SARS-CoV-2
Clinical narrative: c/o cough, headache, dizziness and fatigue. exposed to COVID by wife.  Acute respiratory failure with hypoxemia secondary to COVID; COVID
Age: 64.0
Sex: M
Vaccine: COVID19
Symptoms: Fatigue, Headache
Clinical narrative: c/o cough, headache, dizziness and fatigue. exposed to COVID by wife.  Acute respiratory failure with hypoxemia secondary to COVID; COVID
Age: 67.0
Sex: M
Vaccine: COVID19
Symptoms: Acute respiratory failure, Angiogram pulmonary abnormal, Asthenia, C-reactive protein increased, COVID-19 pneumonia
Clinical narrative: Pneumonia due to COVID 19.; acute hypoxic respiratory failure.  complained of generalzed weakness and non-productive cough with chest tightness. Labs reveal >20 CRP.  CTA positive for  Right sided PE.
Age: 67.0
Sex: M
Vaccine: COVID19
Symptoms: Chest discomfort, Cough, Laboratory test abnormal
Clinical narrative: Pneumonia due to COVID 19.; acute hypoxic respiratory failure.  complained of generalzed weakness and non-productive cough with chest tightness. Labs reveal >20 CRP.  CTA positive for  Right sided PE.
Age: 91.0
Sex: F
Vaccine: COVID19
Symptoms: Symptom recurrence, Transient ischaemic attack
Clinical narrative: TRANSIENT CEREBRAL ISCHEMIA 1/27/2023  --  RECURRENCE OF HOSPITALIZATION WITH SAME SYMPTOMS
Age: 38.0
Sex: F
Vaccine: COVID19
Symptoms: Injection site pain
Clinical narrative: SORE ARM AT INJECTION SITE. RESOLVED IN 2 DAYS Narrative:
Age: 84.0
Sex: M
Vaccine: COVID19
Symptoms: Acute kidney injury, COVID-19, Dyspnoea, Endotracheal intubation, Hypoxia
Clinical narrative: SOB, hypoxia, COVID + at Nursing home. no remdisivir (outside of window); tocilizumab, decadron, intubated; AKI; transfer to hospice
Age: 84.0
Sex: M
Vaccine: COVID19
Symptoms: SARS-CoV-2 test positive
Clinical narrative: SOB, hypoxia, COVID + at Nursing home. no remdisivir (outside of window); tocilizumab, decadron, intubated; AKI; transfer to hospice
Age: 43.0
Sex: M
Vaccine: COVID19
Symptoms: Neuropathy peripheral
Clinical narrative: NEUROPATHY
Age: 88.0
Sex: F
Vaccine: COVID19
Symptoms: Acute respiratory failure, COVID-19, Cough, Dyspnoea, Encephalopathy
Clinical narrative: nausea, vomiting, sob; pnuemonia and COVID; cough and congestion x 2days. on non-rebreather and O2; Acute respiratory failure; encephalopathy
Age: 88.0
Sex: F
Vaccine: COVID19
Symptoms: Nausea, Pneumonia, Respiratory tract congestion, Vomiting
Clinical narrative: nausea, vomiting, sob; pnuemonia and COVID; cough and congestion x 2days. on non-rebreather and O2; Acute respiratory failure; encephalopathy
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Acute kidney injury, COVID-19, Confusional state, Myalgia, Nausea
Clinical narrative: mylagies, nausea, confusion, COVID -a-symptomatic, acute kidney injury
Age: 67.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Diarrhoea, Dyspnoea
Clinical narrative: respiratory failure with hysoxia secondary to COVID;  c/o SOB and diahrrea. treated with IV dexamethasone and abx
Age: 69.0
Sex: M
Vaccine: COVID19
Symptoms: Acute kidney injury, COVID-19, Cardioversion, Chills, Cough
Clinical narrative: fever, chills, runny nose, cough. hypoxic respiratory failure secondary to COVID +; AICD shocked; Acute kidney injury; treatment O2, Zinc, steroids, amioderone. On 3L O2. Did walk study, dc'd home on O2.
Age: 69.0
Sex: M
Vaccine: COVID19
Symptoms: Pyrexia, Respiratory failure, Rhinorrhoea, SARS-CoV-2 test
Clinical narrative: fever, chills, runny nose, cough. hypoxic respiratory failure secondary to COVID +; AICD shocked; Acute kidney injury; treatment O2, Zinc, steroids, amioderone. On 3L O2. Did walk study, dc'd home on O2.
Age: 61.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19 pneumonia, Cardiopulmonary exercise test, Cough, Dyspnoea, Pain
Clinical narrative: SOB, body aches, coughing. hypoxic resp failure secondary to COVID pneumonia. not candidate for remdisiver (outside of window). Dexamethasone, O2, IV fluids; 6 min walk study , no O2 requirement
Age: 61.0
Sex: F
Vaccine: COVID19
Symptoms: Respiratory failure
Clinical narrative: SOB, body aches, coughing. hypoxic resp failure secondary to COVID pneumonia. not candidate for remdisiver (outside of window). Dexamethasone, O2, IV fluids; 6 min walk study , no O2 requirement
Age: 47.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal pain, COVID-19 pneumonia, Cardio-respiratory arrest, Clostridium difficile infection, Deep vein thrombosis
Clinical narrative: admitted for abd pain, upper GI bleed; hypotension; Sent to ICU for COVID PN   -as O2 increased to NRB, then intubation on 2/19. Treat with dexamethasone, given a dose of tocilizumab; pressors.Klebseilla and MSSA PN.  CDIFF and was started and Vanc. (became sepstic due to the Klebsiella, MSSA PN, and CDIFF). Developed DVT, unable to start AC due to severe thrombosytopenia. DEveloped Shock requiring 4 pressors. Eventually developed PEA and arrested.
Age: 47.0
Sex: F
Vaccine: COVID19
Symptoms: Endotracheal intubation, Hypotension, Intensive care, Klebsiella infection, Pulseless electrical activity
Clinical narrative: admitted for abd pain, upper GI bleed; hypotension; Sent to ICU for COVID PN   -as O2 increased to NRB, then intubation on 2/19. Treat with dexamethasone, given a dose of tocilizumab; pressors.Klebseilla and MSSA PN.  CDIFF and was started and Vanc. (became sepstic due to the Klebsiella, MSSA PN, and CDIFF). Developed DVT, unable to start AC due to severe thrombosytopenia. DEveloped Shock requiring 4 pressors. Eventually developed PEA and arrested.
Age: 47.0
Sex: F
Vaccine: COVID19
Symptoms: Sepsis, Shock, Staphylococcal infection, Thrombocytopenia, Upper gastrointestinal haemorrhage
Clinical narrative: admitted for abd pain, upper GI bleed; hypotension; Sent to ICU for COVID PN   -as O2 increased to NRB, then intubation on 2/19. Treat with dexamethasone, given a dose of tocilizumab; pressors.Klebseilla and MSSA PN.  CDIFF and was started and Vanc. (became sepstic due to the Klebsiella, MSSA PN, and CDIFF). Developed DVT, unable to start AC due to severe thrombosytopenia. DEveloped Shock requiring 4 pressors. Eventually developed PEA and arrested.
Age: 71.0
Sex: F
Vaccine: COVID19
Symptoms: Acute kidney injury, Acute myocardial infarction, Acute pulmonary oedema, COVID-19, Dyspnoea
Clinical narrative: SOB, hypoxia, COVID positive. sepsis, NSTEMI, AKI,  Intubated. treatment decadron, cefepime, lasix. PT extubated on 1/24 and reintubated 1/25 due to acute pulm edema. extubated 1/29 to bipap, NC on 1/31.  On RA by DC.
Age: 71.0
Sex: F
Vaccine: COVID19
Symptoms: Endotracheal intubation, Hypoxia, Positive airway pressure therapy, SARS-CoV-2 test positive, Sepsis
Clinical narrative: SOB, hypoxia, COVID positive. sepsis, NSTEMI, AKI,  Intubated. treatment decadron, cefepime, lasix. PT extubated on 1/24 and reintubated 1/25 due to acute pulm edema. extubated 1/29 to bipap, NC on 1/31.  On RA by DC.
Age: 43.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Cough, Diarrhoea, Dyspnoea, Hypoxia
Clinical narrative: Sob, fever, cough, sore troat, hypoxia, pneumonia secondary  to COVID. vomiting diarrhea.  treat with O2 and dexamethasone.  Dc home on O2
Age: 43.0
Sex: F
Vaccine: COVID19
Symptoms: Oropharyngeal pain, Pneumonia, Pyrexia, Vomiting
Clinical narrative: Sob, fever, cough, sore troat, hypoxia, pneumonia secondary  to COVID. vomiting diarrhea.  treat with O2 and dexamethasone.  Dc home on O2
Age: 82.0
Sex: M
Vaccine: COVID19
Symptoms: Deep vein thrombosis, Pulmonary embolism
Clinical narrative: SADDLE PULMONARY EMBOLISM ACUTE DVT OF LEFT POPLITEAL VEIN
Age: 89.0
Sex: F
Vaccine: COVID19
Symptoms: Asthma, COVID-19 pneumonia, Cardiac failure acute, Cardiac failure congestive, Dyspnoea
Clinical narrative: SOB, hypoxia due to COVID Pneumonia. acute on chronic CHF, asthma. dexamethasone, lasix, doxycycline, 2L O2 NC.  Home on RA
Age: 89.0
Sex: F
Vaccine: COVID19
Symptoms: Hypoxia
Clinical narrative: SOB, hypoxia due to COVID Pneumonia. acute on chronic CHF, asthma. dexamethasone, lasix, doxycycline, 2L O2 NC.  Home on RA
Age: 74.0
Sex: F
Vaccine: COVID19
Symptoms: Acute kidney injury, Asthenia, Bladder catheterisation, COVID-19, Decreased appetite
Clinical narrative: weakness, poor appetite, low grade fever; COVID +; O2 on 2L NC. AKI, gental hydration, decadron. Foley Cath. 2/16 Pt more lethargic, O2 increased to 4L NC. able place pt on RA on 2/18. Failed voiding trial, will dc with foley to SNF.
Age: 74.0
Sex: F
Vaccine: COVID19
Symptoms: Lethargy, Pyrexia, SARS-CoV-2 test positive, Trial of void
Clinical narrative: weakness, poor appetite, low grade fever; COVID +; O2 on 2L NC. AKI, gental hydration, decadron. Foley Cath. 2/16 Pt more lethargic, O2 increased to 4L NC. able place pt on RA on 2/18. Failed voiding trial, will dc with foley to SNF.
Age: 35.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Dyspnoea, SARS-CoV-2 test positive, Sinus congestion, Urinary tract infection
Clinical narrative: SOB, sinus congestion, COVID +.  received regeneron prior to admission. Her SOB worsened prompting the ED visit. NO O2 required.UTI - given Meropenem and Ceftriaxone. IV hydration.  dc home on oral abx
Age: 45.0
Sex: M
Vaccine: COVID19
Symptoms: Cerebrovascular accident
Clinical narrative: ACUTE STROKE, UNSPECIFIED TYPE AND ARTERY
Age: 67.0
Sex: M
Vaccine: COVID19
Symptoms: Acute myocardial infarction, Anticoagulant therapy, COVID-19, COVID-19 pneumonia, Cardiac failure acute
Clinical narrative: admit for cough, sore throat, body aches, headache, n/v/d, O2 80% on RA prior to arrival, - COVID +. COVID Pneumonia, hypoxia, acute CHF. O2 @ 4L, dexamethasone, zinc, Vit C, remdisivir X5 days. O2 increased to 50L HF. VQ showed PE placed on heparin gtt. elevated troponin, chest pain - moved to ICU. no cath per cardiologist.  O2 up to 60L high -flow.  EF 35%.  NSTEMI. given toci. up to chair, sats 79-83 on 50L high flow and nonrebreather. pt does not want intubation. using BIPAP and alternating with 60L high flow/nonrebreather.  sating 70 % on 100% bipap. switched back to high FiO2 with high flow NC as well as nonrebreather. pt complained of chest pain, VTAC, coded. Code blue called, CPR started,  Intubatation, fami
Age: 67.0
Sex: M
Vaccine: COVID19
Symptoms: Cardiac failure congestive, Cardio-respiratory arrest, Chest pain, Cough, Diarrhoea
Clinical narrative: admit for cough, sore throat, body aches, headache, n/v/d, O2 80% on RA prior to arrival, - COVID +. COVID Pneumonia, hypoxia, acute CHF. O2 @ 4L, dexamethasone, zinc, Vit C, remdisivir X5 days. O2 increased to 50L HF. VQ showed PE placed on heparin gtt. elevated troponin, chest pain - moved to ICU. no cath per cardiologist.  O2 up to 60L high -flow.  EF 35%.  NSTEMI. given toci. up to chair, sats 79-83 on 50L high flow and nonrebreather. pt does not want intubation. using BIPAP and alternating with 60L high flow/nonrebreather.  sating 70 % on 100% bipap. switched back to high FiO2 with high flow NC as well as nonrebreather. pt complained of chest pain, VTAC, coded. Code blue called, CPR started,  Intubatation, fami
Age: 67.0
Sex: M
Vaccine: COVID19
Symptoms: Endotracheal intubation, Headache, Hypoxia, Intensive care, Nausea
Clinical narrative: admit for cough, sore throat, body aches, headache, n/v/d, O2 80% on RA prior to arrival, - COVID +. COVID Pneumonia, hypoxia, acute CHF. O2 @ 4L, dexamethasone, zinc, Vit C, remdisivir X5 days. O2 increased to 50L HF. VQ showed PE placed on heparin gtt. elevated troponin, chest pain - moved to ICU. no cath per cardiologist.  O2 up to 60L high -flow.  EF 35%.  NSTEMI. given toci. up to chair, sats 79-83 on 50L high flow and nonrebreather. pt does not want intubation. using BIPAP and alternating with 60L high flow/nonrebreather.  sating 70 % on 100% bipap. switched back to high FiO2 with high flow NC as well as nonrebreather. pt complained of chest pain, VTAC, coded. Code blue called, CPR started,  Intubatation, fami
Age: 67.0
Sex: M
Vaccine: COVID19
Symptoms: Oropharyngeal pain, Pain, Positive airway pressure therapy, Resuscitation, SARS-CoV-2 test positive
Clinical narrative: admit for cough, sore throat, body aches, headache, n/v/d, O2 80% on RA prior to arrival, - COVID +. COVID Pneumonia, hypoxia, acute CHF. O2 @ 4L, dexamethasone, zinc, Vit C, remdisivir X5 days. O2 increased to 50L HF. VQ showed PE placed on heparin gtt. elevated troponin, chest pain - moved to ICU. no cath per cardiologist.  O2 up to 60L high -flow.  EF 35%.  NSTEMI. given toci. up to chair, sats 79-83 on 50L high flow and nonrebreather. pt does not want intubation. using BIPAP and alternating with 60L high flow/nonrebreather.  sating 70 % on 100% bipap. switched back to high FiO2 with high flow NC as well as nonrebreather. pt complained of chest pain, VTAC, coded. Code blue called, CPR started,  Intubatation, fami
Age: 67.0
Sex: M
Vaccine: COVID19
Symptoms: Troponin increased, Ventilation/perfusion scan abnormal, Ventricular tachycardia, Vomiting
Clinical narrative: admit for cough, sore throat, body aches, headache, n/v/d, O2 80% on RA prior to arrival, - COVID +. COVID Pneumonia, hypoxia, acute CHF. O2 @ 4L, dexamethasone, zinc, Vit C, remdisivir X5 days. O2 increased to 50L HF. VQ showed PE placed on heparin gtt. elevated troponin, chest pain - moved to ICU. no cath per cardiologist.  O2 up to 60L high -flow.  EF 35%.  NSTEMI. given toci. up to chair, sats 79-83 on 50L high flow and nonrebreather. pt does not want intubation. using BIPAP and alternating with 60L high flow/nonrebreather.  sating 70 % on 100% bipap. switched back to high FiO2 with high flow NC as well as nonrebreather. pt complained of chest pain, VTAC, coded. Code blue called, CPR started,  Intubatation, fami
Age: 60.0
Sex: M
Vaccine: COVID19
Symptoms: Neuropathy peripheral, Symptom recurrence
Clinical narrative: CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY, SUBSEQ NEUROPATHY 10/29/2022,  12/6/2022,  11/20/2022  --  RECURRENCE OF HOSPITALIZATION WITH SAME SYMPTOMS
Age: 73.0
Sex: M
Vaccine: COVID19
Symptoms: Cerebrovascular accident
Clinical narrative: ACUTE LACUNAR STROKE, UNSPECIFIED TYPE AND ARTERY
Age: 62.0
Sex: M
Vaccine: COVID19
Symptoms: Asthenia, COVID-19, Cough, Decreased appetite, Limb injury
Clinical narrative: Presented w/ gen. weakness, decreased appetite, n/v, cough. Prior Covid infection X 3 weeks ago. Also rpts lft foot wound drainage. Treated covid w/ vit C, zinc, singular, antitussies
Age: 62.0
Sex: M
Vaccine: COVID19
Symptoms: Nausea, Vomiting, Wound drainage
Clinical narrative: Presented w/ gen. weakness, decreased appetite, n/v, cough. Prior Covid infection X 3 weeks ago. Also rpts lft foot wound drainage. Treated covid w/ vit C, zinc, singular, antitussies
Age: 73.0
Sex: M
Vaccine: HEPA
Symptoms: Erythema, Wound
Clinical narrative: Patient reports almost two weeks after receiving vaccine developing some redness that appeared like a mosquito bite and then turned into a open area.
Age: 56.0
Sex: M
Vaccine: COVID19
Symptoms: Deep vein thrombosis, Hypoxia, Pulmonary embolism
Clinical narrative: SADDLE PULMONARY EMBOLISM ACUTE DVT OF RIGHT LEG, UNSPECIFIED VEIN ACUTE PULMONARY EMBOLISM HYPOXIA
Age: 68.0
Sex: M
Vaccine: COVID19-2
Symptoms: Injection site pruritus, Injection site reaction, Injection site swelling, Injection site warmth, Scab
Clinical narrative: Vaccine recipient  reported a itchy raised bump with  a crust on the injection site, hot to the touch.
Age: 77.0
Sex: F
Vaccine: FLUA4
Symptoms: Arthralgia, Condition aggravated, Rheumatoid arthritis
Clinical narrative: She got her vaccine, at 6:00 PM her RA started acting up in both hips, severe pain.  Then the left side of her hip subsided the next day.  She started taking Ibuprofen 800 mg, but the left hip has continued to be very very painful.  Her RA was fine prior to the vaccine.  She has left a message for her doctor to call her in this regard.  She also left a message with no call back yet from her rheumatologist that handles her RA.  She has not had an RA problem for about 3 years until she took this vaccine.   She has gotten her flu shot every year and all of her COVID vaccines, and had no problems until now.
Age: 90.0
Sex: M
Vaccine: COVID19
Symptoms: Acute respiratory failure, Anticoagulant therapy, Atrial fibrillation, Bradycardia, COVID-19 pneumonia
Clinical narrative: ground level fall, hypoxia, O2 at 10L oxymask ; + covid PN; acute resp failure; AFIB on eliquis; Zinc, Vit C. Pt experiencing some bradycardia. Made DNR on 2/2. O2 increased to 15 L NRB on 2/3. remdisiver held. Decadron. more lethargic, placed on comfort care.
Age: 90.0
Sex: M
Vaccine: COVID19
Symptoms: Fall, Hypoxia, Lethargy, SARS-CoV-2 test positive
Clinical narrative: ground level fall, hypoxia, O2 at 10L oxymask ; + covid PN; acute resp failure; AFIB on eliquis; Zinc, Vit C. Pt experiencing some bradycardia. Made DNR on 2/2. O2 increased to 15 L NRB on 2/3. remdisiver held. Decadron. more lethargic, placed on comfort care.
Age: 56.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Abdominal pain upper, Alanine aminotransferase increased, Aspartate aminotransferase increased, Blood immunoglobulin A decreased, Blood immunoglobulin G decreased
Clinical narrative: Reaction started within 2 hours after receiving her 2nd Pfizer Vaccine on 3/17/2021.  All over body tremors;  severe adverse body temperature changes from freezing to severe sweating all over;  unable to regulate body temperature normally; intense headache; severe pelvic burning pain; urinary frequency; intense right upper quadrant pain; legs would jerk in the air when standing; horrible onset of restless leg syndrome; onset of high blood pressure; immediate onset of chronic fatigue; all over muscle weakness; intense nightmares & sleeping disturbances; immediate onset of chronic urinary tract infection which has required two years of chronic antibiotics and IV antibiotic port at times; abnormal labs - elevated AST and ALT liver enzymes; low abnormal IGG, IGM and IGA; elevated Red Blood Count, Hemoglobin and Hematocrit; chronic urinary lab cultures; diagnosis, surgery and radiation for Invasive Ductal Carcinoma Breast Cancer.
Age: 56.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Blood immunoglobulin M decreased, Body temperature fluctuation, Breast cancer female, Cancer surgery, Computerised tomogram
Clinical narrative: Reaction started within 2 hours after receiving her 2nd Pfizer Vaccine on 3/17/2021.  All over body tremors;  severe adverse body temperature changes from freezing to severe sweating all over;  unable to regulate body temperature normally; intense headache; severe pelvic burning pain; urinary frequency; intense right upper quadrant pain; legs would jerk in the air when standing; horrible onset of restless leg syndrome; onset of high blood pressure; immediate onset of chronic fatigue; all over muscle weakness; intense nightmares & sleeping disturbances; immediate onset of chronic urinary tract infection which has required two years of chronic antibiotics and IV antibiotic port at times; abnormal labs - elevated AST and ALT liver enzymes; low abnormal IGG, IGM and IGA; elevated Red Blood Count, Hemoglobin and Hematocrit; chronic urinary lab cultures; diagnosis, surgery and radiation for Invasive Ductal Carcinoma Breast Cancer.
Age: 56.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Culture urine, Dyskinesia, Fatigue, Feeling cold, Haematocrit increased
Clinical narrative: Reaction started within 2 hours after receiving her 2nd Pfizer Vaccine on 3/17/2021.  All over body tremors;  severe adverse body temperature changes from freezing to severe sweating all over;  unable to regulate body temperature normally; intense headache; severe pelvic burning pain; urinary frequency; intense right upper quadrant pain; legs would jerk in the air when standing; horrible onset of restless leg syndrome; onset of high blood pressure; immediate onset of chronic fatigue; all over muscle weakness; intense nightmares & sleeping disturbances; immediate onset of chronic urinary tract infection which has required two years of chronic antibiotics and IV antibiotic port at times; abnormal labs - elevated AST and ALT liver enzymes; low abnormal IGG, IGM and IGA; elevated Red Blood Count, Hemoglobin and Hematocrit; chronic urinary lab cultures; diagnosis, surgery and radiation for Invasive Ductal Carcinoma Breast Cancer.
Age: 56.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Haemoglobin increased, Headache, Hyperhidrosis, Hypertension, Invasive ductal breast carcinoma
Clinical narrative: Reaction started within 2 hours after receiving her 2nd Pfizer Vaccine on 3/17/2021.  All over body tremors;  severe adverse body temperature changes from freezing to severe sweating all over;  unable to regulate body temperature normally; intense headache; severe pelvic burning pain; urinary frequency; intense right upper quadrant pain; legs would jerk in the air when standing; horrible onset of restless leg syndrome; onset of high blood pressure; immediate onset of chronic fatigue; all over muscle weakness; intense nightmares & sleeping disturbances; immediate onset of chronic urinary tract infection which has required two years of chronic antibiotics and IV antibiotic port at times; abnormal labs - elevated AST and ALT liver enzymes; low abnormal IGG, IGM and IGA; elevated Red Blood Count, Hemoglobin and Hematocrit; chronic urinary lab cultures; diagnosis, surgery and radiation for Invasive Ductal Carcinoma Breast Cancer.